Stock Groups

Relying on J&J’s analyses to assess vaccine booster dose data -U.S. FDA staff By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – A Johnson and Johnson woman is given the COVID-19 vaccine in Houghton Johannesburg, South Africa on August 20, 2021. REUTERS/ Sumaya Hisham

(Reuters) – U.S. Food and Drug Administration scientists said on Wednesday they did not have time to analyze data submitted by Johnson & Johnson (NYSE:) on a booster dose of its single-dose COVID-19 vaccine, in a rare case where the agency relied on a company’s analyses to brief its advisory panel.

An outside panel of experts will meet on Friday to discuss whether a booster dose of J&J’s vaccine is safe and effective anywhere between two months and six months after taking the original dose.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]